Thomas Parisi, MD
Orthopaedic Surgery · Wauwatosa, WINPI 1003100090
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (47.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Stryker at 43.4% of the total.
Across 51 payments — averaging $131.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$3K
- Zimmer Biomet$2K
- Davol Inc.$900
- Medical Device Business Services, Inc.$421
- Cvrx, Inc.$377
- Amgen$130
- plus $60 from 1 others
Across 9 payments — averaging $1082.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Zimmer Biomet$10K
What the payments were for
- Speaking & faculty fees$90013%
- Travel & lodging$3,20548%
- Food & beverage$2,59939%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 23 | $2,912 |
| Zimmer Biomet | 17 | $1,903 |
| Davol Inc. | 1 | $900 |
| Medical Device Business Services, Inc. | 4 | $421 |
| Cvrx, Inc. | 4 | $377 |
| Amgen | 1 | $130 |
| Johnson & Johnson | 1 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,704 in reported general payments places this provider in the 65th percentile of 498 orthopaedic surgery providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 402 | $5,519 |
| Mupirocin | 349 | $2,962 |
| Amoxicillin | 519 | $1,016 |
| Celecoxib | 29 | $523 |
| Clindamycin Hcl | 105 | $397 |
| Tramadol Hcl | 48 | $340 |
| Tranexamic Acid | 13 | $223 |
| Oxycodone Hcl | 24 | $164 |
| Meloxicam | 50 | $123 |
| Tizanidine Hcl | 25 | $104 |
| Cefadroxil | 13 | $74 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Wauwatosa
- Robert PriorWauwatosa$63K
- Robert ChurchillGrafton$7.7M
- Richard IllgenMadison$6.1M
- Jeffrey McLaughlinOshkosh$2M
- Clifford TribusMadison$1.4M
- Thomas ZdeblickMadison$1.1M
- Justin MitchellOnalaska$666K
- Christopher BibboStevens Point$615K
- Robert LimoniAppleton$514K
- Paul AndersonVerona$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.